Skip to main content
. 2022 May 5;42(9):1732–1747. doi: 10.1177/0271678X221099092

Figure 6.

Figure 6.

Dabigatran prevents α-thrombin-induced loss of microvessel basal lamina matrix proteins in vivo. In a balanced factorial design, employing 32 animals, stereotaxic striatal injection of 40 mU α-thrombin significantly decreased microvessel basal lamina collagen IV (α1-chain), laminin (β1-chain), and perlecan immunoreactivity (black bars) compared to placebo in subjects fed placebo-containing chow, while dabigatran ingestion prevented this decrease (white bars). Upper graph. Collagen IV. A GLM analysis of subsequent microvessel collagen IV (α1-chain) immunoreactivity with main effects α-thrombin and dabigatran, found a significant α-thrombin effect (p = 0.001), a borderline significant dabigatran effect (p = 0.063), and a large α-thrombin × dabigatran interaction (p = 0.001), owing to the significantly lower level of collagen IV immunoreactivity (placebo chow–α-thrombin group). Middle graph. Laminin. Similarly, for the laminin β1-chain a significant α-thrombin effect (p = 0.019), a non-significant dabigatran effect (p = 0.125), and a significant α-thrombin × dabigatran interaction (p = 0.036) were found, owing to the significantly lower level of laminin immunoreactivity (placebo chow–α-thrombin group). Lower graph. Perlecan.Continued.For microvessel perlecan immunoreactivity significant main effects for α-thrombin (p = 0.002) and for dabigatran (p = 0.008) and a significant α-thrombin × dabigatran interaction (p = 0.005) were found. The significant interaction owes to the significantly decreased perlecan immunoreactivity in the placebo chow–α-thrombin group relative to the other groups (Bonferroni, α = 0.05).